Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
The activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab combined with oxaliplatin/leucovorin/5-fluorouracil (FUFOX) was assessed in first-line metastatic gastric and oesophago-gastric junction (OGJ) cancer in a prospective phase II study showing a promising...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2011
|
| In: |
BMC cancer
Year: 2011, Jahrgang: 11, Pages: 1-12 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/1471-2407-11-509 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-11-509 Verlag, lizenzpflichtig, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-509 
|
| Verfasserangaben: | Birgit Luber, Joëlle Deplazes, Gisela Keller, Axel Walch, Sandra Rauser, Martin Eichmann, Rupert Langer, Heinz Höfler, Susanna Hegewisch-Becker, Gunnar Folprecht, Ewald Wöll, Thomas Decker, Esther Endlicher, Sylvie Lorenzen, Falko Fend, Christian Peschel and Florian Lordick |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1821586190 | ||
| 003 | DE-627 | ||
| 005 | 20230710102906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221110s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/1471-2407-11-509 |2 doi | |
| 035 | |a (DE-627)1821586190 | ||
| 035 | |a (DE-599)KXP1821586190 | ||
| 035 | |a (OCoLC)1389753228 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Luber, Birgit |e VerfasserIn |0 (DE-588)114723265 |0 (DE-627)512028699 |0 (DE-576)289806275 |4 aut | |
| 245 | 1 | 0 | |a Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer |b results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) |c Birgit Luber, Joëlle Deplazes, Gisela Keller, Axel Walch, Sandra Rauser, Martin Eichmann, Rupert Langer, Heinz Höfler, Susanna Hegewisch-Becker, Gunnar Folprecht, Ewald Wöll, Thomas Decker, Esther Endlicher, Sylvie Lorenzen, Falko Fend, Christian Peschel and Florian Lordick |
| 246 | 3 | 0 | |a two |
| 264 | 1 | |c 2011 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.11.2022 | ||
| 520 | |a The activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab combined with oxaliplatin/leucovorin/5-fluorouracil (FUFOX) was assessed in first-line metastatic gastric and oesophago-gastric junction (OGJ) cancer in a prospective phase II study showing a promising objective tumour response rate of 65% and a low mutation frequency of KRAS (3%). The aim of the correlative tumour tissue studies was to investigate the relationship between EGFR gene copy numbers, activation of the EGFR pathway, expression and mutation of E-cadherin, V600E BRAF mutation and clinical outcome of patients with gastric and OGJ cancer treated with cetuximab combined with FUFOX. | ||
| 650 | 4 | |a Cetuximab | |
| 650 | 4 | |a Epidermal Growth Factor Receptor | |
| 650 | 4 | |a Epidermal Growth Factor Receptor Expression | |
| 650 | 4 | |a Overall Response Rate | |
| 650 | 4 | |a Overall Survival | |
| 700 | 1 | |a Deplazes, Joëlle |e VerfasserIn |4 aut | |
| 700 | 1 | |a Keller, Gisela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Walch, Axel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rauser, Sandra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eichmann, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Langer, Rupert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Höfler, Heinz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hegewisch-Becker, Susanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Folprecht, Gunnar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wöll, Ewald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Decker, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Endlicher, Esther |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lorenzen, Sylvie |d 1973- |e VerfasserIn |0 (DE-588)128891106 |0 (DE-627)384629202 |0 (DE-576)297385739 |4 aut | |
| 700 | 1 | |a Fend, Falko |e VerfasserIn |4 aut | |
| 700 | 1 | |a Peschel, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lordick, Florian |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 11(2011), Artikel-ID 509, Seite 1-12 |h Online-Ressource |w (DE-627)326643710 |w (DE-600)2041352-X |w (DE-576)107014645 |x 1471-2407 |7 nnas |a Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) |
| 773 | 1 | 8 | |g volume:11 |g year:2011 |g elocationid:509 |g pages:1-12 |g extent:12 |a Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) |
| 856 | 4 | 0 | |u https://doi.org/10.1186/1471-2407-11-509 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-509 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221110 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 128891106 |a Lorenzen, Sylvie |m 128891106:Lorenzen, Sylvie |d 50000 |e 50000PL128891106 |k 0/50000/ |p 14 | ||
| 999 | |a KXP-PPN1821586190 |e 4208507519 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 10.11.2022"],"language":["eng"],"recId":"1821586190","title":[{"subtitle":"results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","title":"Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer","title_sort":"Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer"}],"person":[{"given":"Birgit","family":"Luber","role":"aut","roleDisplay":"VerfasserIn","display":"Luber, Birgit"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Deplazes, Joëlle","given":"Joëlle","family":"Deplazes"},{"family":"Keller","given":"Gisela","roleDisplay":"VerfasserIn","display":"Keller, Gisela","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Walch, Axel","role":"aut","family":"Walch","given":"Axel"},{"display":"Rauser, Sandra","roleDisplay":"VerfasserIn","role":"aut","family":"Rauser","given":"Sandra"},{"roleDisplay":"VerfasserIn","display":"Eichmann, Martin","role":"aut","family":"Eichmann","given":"Martin"},{"roleDisplay":"VerfasserIn","display":"Langer, Rupert","role":"aut","family":"Langer","given":"Rupert"},{"given":"Heinz","family":"Höfler","role":"aut","display":"Höfler, Heinz","roleDisplay":"VerfasserIn"},{"display":"Hegewisch-Becker, Susanna","roleDisplay":"VerfasserIn","role":"aut","family":"Hegewisch-Becker","given":"Susanna"},{"given":"Gunnar","family":"Folprecht","role":"aut","roleDisplay":"VerfasserIn","display":"Folprecht, Gunnar"},{"display":"Wöll, Ewald","roleDisplay":"VerfasserIn","role":"aut","family":"Wöll","given":"Ewald"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Decker, Thomas","given":"Thomas","family":"Decker"},{"given":"Esther","family":"Endlicher","role":"aut","roleDisplay":"VerfasserIn","display":"Endlicher, Esther"},{"given":"Sylvie","family":"Lorenzen","role":"aut","display":"Lorenzen, Sylvie","roleDisplay":"VerfasserIn"},{"family":"Fend","given":"Falko","display":"Fend, Falko","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Peschel","given":"Christian","display":"Peschel, Christian","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Lordick, Florian","roleDisplay":"VerfasserIn","role":"aut","family":"Lordick","given":"Florian"}],"physDesc":[{"extent":"12 S."}],"relHost":[{"part":{"pages":"1-12","year":"2011","extent":"12","text":"11(2011), Artikel-ID 509, Seite 1-12","volume":"11"},"pubHistory":["1.2001 -"],"recId":"326643710","language":["eng"],"note":["Gesehen am 22.05.20"],"disp":"Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)BMC cancer","type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"BMC cancer","title_sort":"BMC cancer"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["326643710"],"zdb":["2041352-X"],"issn":["1471-2407"]},"origin":[{"dateIssuedDisp":"2001-","publisher":"BioMed Central ; Springer","dateIssuedKey":"2001","publisherPlace":"London ; Berlin ; Heidelberg"}]}],"origin":[{"dateIssuedDisp":"2011","dateIssuedKey":"2011"}],"id":{"eki":["1821586190"],"doi":["10.1186/1471-2407-11-509"]},"name":{"displayForm":["Birgit Luber, Joëlle Deplazes, Gisela Keller, Axel Walch, Sandra Rauser, Martin Eichmann, Rupert Langer, Heinz Höfler, Susanna Hegewisch-Becker, Gunnar Folprecht, Ewald Wöll, Thomas Decker, Esther Endlicher, Sylvie Lorenzen, Falko Fend, Christian Peschel and Florian Lordick"]}} | ||
| SRT | |a LUBERBIRGIBIOMARKERA2011 | ||